In this episode, “CAR T-cell Therapy Democratization vs Alternative Cancer Treatments,” join Chris Montalbano, CEO and Co-Founder of MIDI, shares his expert insights into the groundbreaking field of CAR T-cell Therapy. As a leader in biopharmaceutical innovation, Chris discusses how this cutting-edge treatment is transforming the landscape of cancer therapy.
- Historical Milestones: The journey of CAR T-cell Therapy since the first FDA approval in 2017, leading to about 10 approved drugs today, with many more in development.
- Targeted Precision: Learn how CAR T-cell Therapy uniquely targets cancer cells while preserving healthy ones, offering a promising alternative to traditional treatments.
- Overcoming Challenges: Discover strategies to overcome the time and cost barriers in production, enabling high-volume scalability, reducing costs per therapy, and accelerating production turnaround.
Learn about this Point-of-Care Revolution.
Explore the innovative Point-of-Care (POC) approach that allows biopharma products to be manufactured at or near the patient’s treatment site. This methodology not only speeds up access to therapy but also democratizes cancer treatment, making it accessible to a broader patient population.
Listen to this Series and Be Inspired.
Join us as we delve into the dynamic world of CAR T-cell Therapy. Gain valuable knowledge on how this revolutionary treatment can make a profound difference in cancer care.